SLAMF7 and diffuse large B-cell lymphoma: Next, we evaluated the potential clinical impact of SLAMF7 on CD47 blocking, specifically in the context of combination with the clinically relevant antibody rituximab, which is part of the standard-of-care treatment for DLBCL patients.